Clear Street lowered the firm’s price target on Janux Therapeutics (JANX) to $32 from $80 and keeps a Buy rating on the shares. The firm cites “more pragmatic” market entry timelines for the target cut. It views the updated Phase 1 data for JANX007 as highlighting a “thoughtful development process.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Buy Rating Affirmed for Janux Therapeutics Inc: JANX007’s Potential Amid Market Overreaction
- Promising Clinical Trial Results and Strong Financial Position Drive Buy Rating for Janux Therapeutics Inc.
- Closing Bell Movers: MongoDB jumps 22% on earnings beat and raise
- Janux Therapeutics down 46% at $18.50 after JANX007 Phase 1 data in mCRPC
- Janux Therapeutics reports ‘positive’ updated interim data for JANX007